# 4D Molecular Therapeutics, Inc.: financial statements, quarterly

FDMT · Nasdaq · CIK 1650648 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/fdmt.md) · [Financials](/companies/fdmt/financials.md) · [Filings](/companies/fdmt/filings.md) · [Insiders](/companies/fdmt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/fdmt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [20.2](/filings/0000950170-24-126370.md) | [(0.0) d](/filings/0000950170-25-030056.md) | [0.0](/filings/0000950170-25-067040.md) | [0.0](/filings/0000950170-25-106244.md) | [0.0](/filings/0001193125-25-273343.md) | [0.0 d](/filings/0001193125-26-114075.md) | [0.0](/filings/0001193125-26-211939.md) | [0.0](/filings/0001193125-26-349173.md) | [0.1](/filings/0001193125-25-273343.md) | [85.1 d](/filings/0001193125-26-114075.md) | [3.0](/filings/0001193125-26-211939.md) | [3.8](/filings/0001193125-26-349173.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(14.0)](/filings/0000950170-24-126370.md) | [(36.7) d](/filings/0000950170-25-030056.md) | [(38.1)](/filings/0000950170-25-067040.md) | [(42.5)](/filings/0000950170-25-106244.md) | [(51.1)](/filings/0001193125-25-273343.md) | [(56.1) d](/filings/0001193125-26-114075.md) | [(53.6)](/filings/0001193125-26-211939.md) | [(59.5)](/filings/0001193125-26-349173.md) | [(61.2)](/filings/0001193125-25-273343.md) | [14.7 d](/filings/0001193125-26-114075.md) | [(73.6)](/filings/0001193125-26-211939.md) | [(77.0)](/filings/0001193125-26-349173.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-126370.md) | [0.0 d](/filings/0000950170-25-030056.md) | [0.0](/filings/0000950170-25-067040.md) | [0.0](/filings/0000950170-25-106244.md) | [0.0](/filings/0001193125-25-273343.md) | [0.0 d](/filings/0001193125-26-114075.md) | [0.0](/filings/0001193125-26-211939.md) | [0.0](/filings/0001193125-26-349173.md) | [0.0](/filings/0001193125-25-273343.md) | [0.0 d](/filings/0001193125-26-114075.md) | [0.0](/filings/0001193125-26-211939.md) | [0.0](/filings/0001193125-26-349173.md) |
| Net income | $m | [(10.3)](/filings/0000950170-24-126370.md) | [(32.3) d](/filings/0000950170-25-030056.md) | [(32.4)](/filings/0001193125-25-273343.md) | [(35.0)](/filings/0001193125-25-273343.md) | [(43.8)](/filings/0001193125-25-273343.md) | [(49.7) d](/filings/0001193125-26-114075.md) | [(48.0)](/filings/0001193125-26-349173.md) | [(54.7)](/filings/0001193125-26-349173.md) | [(56.9)](/filings/0001193125-25-273343.md) | [19.4 d](/filings/0001193125-26-114075.md) | [(68.8)](/filings/0001193125-26-349173.md) | [(72.9)](/filings/0001193125-26-349173.md) |
| Diluted EPS | $ per share | [(0.24)](/filings/0000950170-24-126370.md) | not reported | [(0.66)](/filings/0000950170-25-067040.md) | [(0.63)](/filings/0000950170-25-106244.md) | [(0.79)](/filings/0001193125-25-273343.md) | not reported | [(0.86)](/filings/0001193125-26-211939.md) | [(0.98)](/filings/0001193125-26-349173.md) | [(1.01)](/filings/0001193125-25-273343.md) | not reported | [(1.01)](/filings/0001193125-26-211939.md) | [(1.04)](/filings/0001193125-26-349173.md) |
| Basic EPS | $ per share | [(0.24)](/filings/0000950170-24-126370.md) | not reported | [(0.66)](/filings/0000950170-25-067040.md) | [(0.63)](/filings/0000950170-25-106244.md) | [(0.79)](/filings/0001193125-25-273343.md) | not reported | [(0.86)](/filings/0001193125-26-211939.md) | [(0.98)](/filings/0001193125-26-349173.md) | [(1.01)](/filings/0001193125-25-273343.md) | not reported | [(1.01)](/filings/0001193125-26-211939.md) | [(1.04)](/filings/0001193125-26-349173.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [276](/filings/0000950170-23-062103.md) | [249](/filings/0000950170-25-030056.md) | [276](/filings/0000950170-24-056933.md) | [189](/filings/0000950170-24-094010.md) | [188](/filings/0000950170-24-126370.md) | [149](/filings/0001193125-26-114075.md) | [134](/filings/0000950170-25-067040.md) | [77.2](/filings/0000950170-25-106244.md) | [48.6](/filings/0001193125-25-273343.md) | [60.2](/filings/0001193125-26-349173.md) | [72.5](/filings/0001193125-26-211939.md) | [70.4](/filings/0001193125-26-349173.md) |
| Current assets | $m | [328](/filings/0000950170-23-062103.md) | [297](/filings/0000950170-25-030056.md) | [536](/filings/0000950170-24-056933.md) | [553](/filings/0000950170-24-094010.md) | [511](/filings/0000950170-24-126370.md) | [435](/filings/0001193125-26-114075.md) | [333](/filings/0000950170-25-067040.md) | [303](/filings/0000950170-25-106244.md) | [312](/filings/0001193125-25-273343.md) | [413](/filings/0001193125-26-349173.md) | [405](/filings/0001193125-26-211939.md) | [383](/filings/0001193125-26-349173.md) |
| Total assets | $m | [362](/filings/0000950170-23-062103.md) | [340](/filings/0000950170-25-030056.md) | [630](/filings/0000950170-24-056933.md) | [620](/filings/0000950170-24-094010.md) | [604](/filings/0000950170-24-126370.md) | [560](/filings/0001193125-26-114075.md) | [516](/filings/0000950170-25-067040.md) | [474](/filings/0000950170-25-106244.md) | [424](/filings/0001193125-25-273343.md) | [567](/filings/0001193125-26-349173.md) | [513](/filings/0001193125-26-211939.md) | [493](/filings/0001193125-26-349173.md) |
| Current liabilities | $m | [18.2](/filings/0000950170-23-062103.md) | [19.0](/filings/0000950170-25-030056.md) | [16.4](/filings/0000950170-24-056933.md) | [19.4](/filings/0000950170-24-094010.md) | [29.5](/filings/0000950170-24-126370.md) | [29.1](/filings/0001193125-26-114075.md) | [26.9](/filings/0000950170-25-067040.md) | [34.7](/filings/0000950170-25-106244.md) | [37.1](/filings/0001193125-25-273343.md) | [44.0](/filings/0001193125-26-349173.md) | [43.4](/filings/0001193125-26-211939.md) | [47.7](/filings/0001193125-26-349173.md) |
| Total liabilities | $m | [31.7](/filings/0000950170-23-062103.md) | [32.1](/filings/0000950170-25-030056.md) | [29.3](/filings/0000950170-24-056933.md) | [31.8](/filings/0000950170-24-094010.md) | [51.1](/filings/0000950170-24-126370.md) | [49.8](/filings/0001193125-26-114075.md) | [46.0](/filings/0000950170-25-067040.md) | [52.7](/filings/0000950170-25-106244.md) | [55.0](/filings/0001193125-25-273343.md) | [61.0](/filings/0001193125-26-349173.md) | [61.1](/filings/0001193125-26-211939.md) | [85.0](/filings/0001193125-26-349173.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-349173.md) | not reported | [19.6](/filings/0001193125-26-349173.md) |
| Shareholders' equity | $m | [330](/filings/0000950170-24-126370.md) | [308](/filings/0001193125-26-114075.md) | [601](/filings/0001193125-25-273343.md) | [588](/filings/0001193125-25-273343.md) | [553](/filings/0001193125-25-273343.md) | [511](/filings/0001193125-26-349173.md) | [470](/filings/0001193125-26-349173.md) | [421](/filings/0001193125-26-349173.md) | [369](/filings/0001193125-25-273343.md) | [506](/filings/0001193125-26-349173.md) | [452](/filings/0001193125-26-349173.md) | [408](/filings/0001193125-26-349173.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(1.2) d](/filings/0000950170-24-126370.md) | [(24.7) d](/filings/0000950170-25-030056.md) | [(29.1)](/filings/0000950170-25-067040.md) | [(30.2) d](/filings/0000950170-25-106244.md) | [(29.4) d](/filings/0001193125-25-273343.md) | [(45.9) d](/filings/0001193125-26-114075.md) | [(47.8)](/filings/0001193125-26-211939.md) | [(43.4) d](/filings/0001193125-26-349173.md) | [(46.5) d](/filings/0001193125-25-273343.md) | [28.6 d](/filings/0001193125-26-114075.md) | [(68.1)](/filings/0001193125-26-211939.md) | [(70.0) d](/filings/0001193125-26-349173.md) |
| Capital expenditure | $m | [0.4 d](/filings/0000950170-24-126370.md) | [0.5 d](/filings/0000950170-25-030056.md) | [0.7](/filings/0000950170-25-067040.md) | [0.3 d](/filings/0000950170-25-106244.md) | [1.8 d](/filings/0001193125-25-273343.md) | [0.9 d](/filings/0001193125-26-114075.md) | [0.6](/filings/0000950170-25-067040.md) | [0.1 d](/filings/0001193125-26-349173.md) | [(0.1) d](/filings/0001193125-25-273343.md) | [(0.1) d](/filings/0001193125-26-114075.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [32.4](/filings/0000950170-23-062103.md) | [32.7](/filings/0000950170-24-056933.md) | [38.3](/filings/0000950170-24-094010.md) | [42.3](/filings/0000950170-24-126370.md) | [49.3](/filings/0000950170-25-067040.md) | [55.3](/filings/0000950170-25-106244.md) | [55.6](/filings/0001193125-25-273343.md) | [55.7](/filings/0001193125-26-211939.md) | [55.9](/filings/0001193125-26-349173.md) | [56.1](/filings/0001193125-25-273343.md) | [68.1](/filings/0001193125-26-211939.md) | [70.3](/filings/0001193125-26-349173.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 49,778,127 at 2024-02-23, from the cover of the [10-K filed 2024-02-29](/filings/0000950170-24-023183.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.